Stock listing
NASDAQ:AXGN Axogen, Inc. Stock
Home listing (NASDAQ) of Axogen, Inc.
Follow Axogen, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:AXGN
$55.75 USD -1.20 (-2.1%)
Close on Nov 20, 2026
- Day range
- $55.03 – $56.91 USDNov 20, 2026
- Volume
- 875,449 sharesNov 20, 2026
- Market cap
- $3.33B USDAt the close on Nov 20, 2026 · price × 59.73M shares outstanding
- 52-week range
- $25.21 – $59.72 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $71.29M USDMedian day 1.21M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AXGN · Home | $55.75 USD | -1.20 (-2.1%) | 875,449 | $55.71 | $56.91 | $55.03 | $56.95 | Close on Nov 20, 2026 |
| LSE:0HKD | $55.97 USD | -0.91 (-1.6%) | 586 | $56.16 | $57.07 | $55.00 | $56.88 | Close on Nov 20, 2026 |
| Frankfurt:LT3 | €50.82 EUR | -0.84 (-1.6%) | — | €50.44 | €50.82 | €50.44 | €51.66 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AXGN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $55.75 | -1.20 | -2.1% | $55.71 | $56.91 | $55.03 | 875,449 | |
| $56.95 | +1.58 | +2.9% | $55.29 | $57.59 | $55.00 | 2,113,783 | |
| $55.37 | -0.01 | 0.0% | $55.15 | $56.87 | $54.50 | 1,352,271 | |
| $55.38 | -0.55 | -1.0% | $55.56 | $56.35 | $55.00 | 1,186,265 | |
| $55.93 | +0.53 | +1.0% | $55.78 | $57.46 | $55.01 | 1,380,323 | |
| $55.40 | -3.23 | -5.5% | $57.75 | $58.30 | $53.87 | 3,054,877 | |
| $58.63 | +7.74 | +15.2% | $50.93 | $59.72 | $50.62 | 4,412,988 | |
| $50.89 | +0.25 | +0.5% | $49.70 | $51.10 | $49.23 | 1,105,728 | |
| $50.64 | +0.62 | +1.2% | $50.92 | $51.48 | $49.48 | 1,297,949 | |
| $50.02 | +1.27 | +2.6% | $48.55 | $50.29 | $48.14 | 1,576,372 | |
| $48.75 | -2.60 | -5.1% | $51.62 | $51.85 | $47.58 | 1,210,034 | |
| $51.35 | +1.85 | +3.7% | $50.28 | $52.75 | $50.08 | 1,786,466 | |
| $49.50 | -0.35 | -0.7% | $50.49 | $50.84 | $49.18 | 1,037,404 | |
| $49.85 | +0.48 | +1.0% | $49.46 | $50.54 | $49.04 | 1,842,470 | |
| $49.37 | -0.26 | -0.5% | $49.70 | $49.88 | $48.08 | 1,833,100 | |
| $49.63 | +0.38 | +0.8% | $49.61 | $51.16 | $48.39 | 2,280,900 | |
| $49.25 | +11.79 | +31.5% | $45.45 | $49.97 | $43.50 | 9,288,600 | |
| $37.46 | -0.56 | -1.5% | $38.14 | $39.04 | $37.23 | 2,457,800 | |
| $38.02 | -0.04 | -0.1% | $38.06 | $38.71 | $37.71 | 1,021,700 | |
| $38.06 | +1.38 | +3.8% | $36.64 | $38.33 | $36.60 | 2,192,100 | |
| $36.68 | +0.20 | +0.5% | $36.48 | $37.29 | $36.21 | 961,600 | |
| $36.48 | +0.31 | +0.9% | $36.01 | $37.47 | $36.00 | 1,131,500 | |
| $36.17 | +0.93 | +2.6% | $35.71 | $36.84 | $35.56 | 974,400 | |
| $35.24 | +0.62 | +1.8% | $34.86 | $35.26 | $34.11 | 782,500 | |
| $34.62 | -1.01 | -2.8% | $35.63 | $35.65 | $34.40 | 1,143,200 | |
| $35.63 | +0.49 | +1.4% | $35.14 | $36.42 | $35.14 | 986,000 | |
| $35.14 | -1.03 | -2.8% | $35.91 | $36.55 | $35.03 | 1,172,000 | |
| $36.17 | -0.94 | -2.5% | $37.20 | $37.40 | $35.83 | 2,136,600 | |
| $37.11 | +0.98 | +2.7% | $36.80 | $37.31 | $35.72 | 1,606,500 | |
| $36.13 | -0.05 | -0.1% | $36.35 | $36.80 | $35.60 | 929,800 | |
| $36.18 | +0.14 | +0.4% | $35.98 | $36.32 | $35.44 | 1,378,200 | |
| $36.04 | -0.27 | -0.7% | $36.31 | $36.88 | $35.83 | 1,602,400 | |
| $36.31 | -0.91 | -2.4% | $37.23 | $37.61 | $35.82 | 2,354,700 | |
| $37.22 | -0.17 | -0.5% | $37.47 | $38.27 | $36.79 | 2,186,500 | |
| $37.39 | -2.53 | -6.3% | $39.92 | $39.92 | $36.97 | 3,098,400 | |
| $39.92 | -2.00 | -4.8% | $41.56 | $42.20 | $39.68 | 1,600,600 | |
| $41.92 | -0.52 | -1.2% | $42.35 | $43.09 | $41.75 | 1,089,100 | |
| $42.44 | -0.92 | -2.1% | $43.67 | $43.79 | $41.76 | 1,407,700 | |
| $43.36 | -0.03 | -0.1% | $43.23 | $43.94 | $42.46 | 885,500 | |
| $43.39 | +0.07 | +0.2% | $43.61 | $44.68 | $43.05 | 1,221,900 | |
| $43.32 | 0.00 | 0.0% | $43.18 | $43.95 | $42.55 | 796,600 | |
| $43.32 | -1.22 | -2.7% | $44.54 | $44.84 | $43.25 | 1,247,100 | |
| $44.54 | -1.39 | -3.0% | $46.17 | $47.00 | $44.00 | 1,331,500 | |
| $45.93 | +1.70 | +3.8% | $44.82 | $46.58 | $44.32 | 1,199,800 | |
| $44.23 | -1.06 | -2.3% | $44.94 | $45.66 | $44.16 | 1,124,500 | |
| $45.29 | -0.15 | -0.3% | $45.91 | $46.89 | $45.07 | 831,400 | |
| $45.44 | +0.47 | +1.0% | $44.87 | $46.35 | $44.03 | 1,423,700 | |
| $44.97 | +1.19 | +2.7% | $43.85 | $45.46 | $43.51 | 1,397,000 | |
| $43.78 | +1.62 | +3.8% | $41.55 | $44.00 | $41.55 | 1,668,200 | |
| $42.16 | +0.31 | +0.7% | $42.48 | $42.59 | $39.62 | 3,477,600 | |
| $41.85 | -5.42 | -11.5% | $45.14 | $45.50 | $41.74 | 3,793,200 | |
| $47.27 | +0.58 | +1.2% | $46.21 | $48.11 | $46.00 | 728,800 | |
| $46.69 | -1.59 | -3.3% | $47.19 | $47.98 | $46.26 | 541,500 | |
| $48.28 | +1.18 | +2.5% | $46.73 | $48.39 | $46.29 | 550,100 | |
| $47.10 | -1.20 | -2.5% | $48.66 | $49.06 | $46.79 | 951,200 | |
| $48.30 | -1.58 | -3.2% | $50.15 | $51.50 | $47.83 | 789,700 | |
| $49.88 | -0.88 | -1.7% | $50.64 | $51.00 | $49.29 | 596,600 | |
| $50.76 | -0.71 | -1.4% | $50.97 | $51.18 | $49.63 | 878,100 | |
| $51.47 | -0.26 | -0.5% | $51.55 | $52.43 | $50.94 | 771,200 | |
| $51.73 | +0.15 | +0.3% | $51.88 | $52.91 | $51.16 | 951,500 | |
| $51.58 | +1.65 | +3.3% | $50.04 | $51.99 | $49.25 | 847,600 | |
| $49.93 | +0.70 | +1.4% | $49.68 | $50.00 | $48.76 | 537,300 | |
| $49.23 | -1.17 | -2.3% | $50.88 | $50.88 | $48.74 | 704,100 | |
| $50.40 | +3.96 | +8.5% | $46.50 | $51.06 | $46.24 | 1,779,700 | |
| $46.44 | -2.49 | -5.1% | $48.45 | $49.18 | $45.26 | 1,033,700 |
Splits
1 split · NASDAQ:AXGN · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 21-for-20 | Split |
- Ticker
- NASDAQ:AXGN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 3, 2026
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Latest earnings call · Oct 28, 2026
Axogen (NASDAQ:AXGN) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 9, 2026
Investor Day (November 2026)
Investor day · 18 slides
Latest news
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Nov 3, 2026
Closed $49.50 (-0.7%) on Nov 3, 2026
Axogen, Inc. Reports Third Quarter 2026 Financial Results
Oct 28, 2026
Closed $49.25 (+31.5%) on Oct 28, 2026
Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026
Oct 14, 2026
Closed $35.14 (-2.8%) on Oct 14, 2026
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
Oct 1, 2026
Closed $37.39 (-6.3%) on Oct 2, 2026
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
Sep 10, 2026
Closed $41.85 (-11.5%) on Sep 10, 2026
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Sep 10, 2026
Closed $41.85 (-11.5%) on Sep 10, 2026
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
Sep 1, 2026
Closed $49.88 (-1.7%) on Sep 1, 2026
Axogen, Inc. Reports Second Quarter 2026 Financial Results
Jul 29, 2026
Closed $41.37 (+0.5%) on Jul 29, 2026
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
Jul 15, 2026
Closed $38.72 (-0.1%) on Jul 15, 2026
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
Apr 30, 2026
Closed $43.20 (+3.4%) on Apr 30, 2026
Axogen, Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 21 in the last 12 months · 155 in all · newest Nov 3, 2026 · oldest 2019
- Calls
- 27 calls with a replay · 27 with a transcript · latest Oct 28, 2026
- Decks
- 36 decks · latest Nov 9, 2026
Where Axogen, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AXGN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:AXGN | BOATS | United States | USD |
| Lang & Schwarz:A1JMHK | Lang & Schwarz | Germany | EUR |
| LSE:0HKD | LSE | United Kingdom | USD |
| Frankfurt:LT3 | Frankfurt | Germany | EUR |
| Tradegate:LT3 | Tradegate | Germany | EUR |
| Stuttgart:LT3 | Stuttgart | Germany | EUR |
| BMV:AXGN | BMV | Mexico | MXN |
Valuation
EV/sales 11.2× against a median of 3.6×: 9th lowest of 11 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.98B USD
- P/E
- Loss
- EV/sales
- 11.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 6.7×
- Gross margin
- 74.2%
- Operating margin
- −5.2%
- Net margin
- −12.0%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.98
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Axogen, Inc. · NASDAQ:AXGN | US$3.33B | US$2.98B | n/a | 11.2× | n/a | 6.7× | −12.0% | 0.0× | 0.98 |
| IMEIK Technology Development Co., Ltd. Class A · SZSE:300896 | US$3.67B | US$3.13B | 24.8× | 9.0× | n/a | 3.1× | 42.4% | 0.0× | n/a |
| Envista Holdings Corporation · NYSE:NVST | US$3.67B | US$3.94B | 5.8× | 1.4× | 4.7× | 1.2× | 22.0% | 0.5× | 1.18 |
| Shandong Weigao Blood Purification Products Co., Ltd. Class A · SSE:603014 | US$3.53B | US$2.97B | 23.4× | 3.7× | n/a | 2.2× | 18.6% | 0.0× | n/a |
| Pulse Biosciences, Inc · NASDAQ:PLSE | US$3.35B | US$3.17B | n/a | 2,120× | n/a | 18.3× | n/a | 0.0× | 1.54 |
| Zhende Medical Co., Ltd. Class A · SSE:603301 | US$3.23B | US$3.13B | 73.1× | 4.5× | n/a | 3.8× | 6.3% | 0.1× | n/a |
| Lepu Medical Technology (Beijing) Co., Ltd. Class A · SZSE:300003 | US$3.09B | US$3.03B | 31.4× | 3.3× | n/a | 1.3× | 10.7% | 0.2× | n/a |
| Carl Zeiss Meditec AG · XETR:AFX | US$3.06B | US$3.06B | 23.9× | 1.1× | n/a | 1.3× | 4.4% | 0.0× | n/a |
| Imricor Medical Systems, Inc. · ASX:IMR | US$2.99B | US$2.96B | n/a | 9,790× | n/a | 103× | n/a | 1.2× | n/a |
| TransMedics Group, Inc. · NASDAQ:TMDX | US$2.96B | US$2.52B | 20.5× | 3.5× | 19.8× | 5.4× | 19.9% | 0.1× | 1.31 |
| Ambu A/S Class B · OMXCOP:AMBU_B | US$2.92B | US$2.92B | 30.9× | 3.1× | 15.9× | 3.2× | 9.9% | 0.1× | n/a |
| Median of the others | US$3.16B | US$3.04B | 24.4× | 3.6× | 15.9× | 3.2× | 14.6% | 0.1× | 1.31 |
Forecasts
9 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 59.27 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.55 · 9 analysts
- Revenue, year to Dec 2026
- 290.4M · 10 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Michael Dale | President, Chief Executive Officer and Board Director |
| Lindsey Hartley | Chief Financial Officer |
| Marc Began | Executive Vice President and General Counsel |
| Doris Quackenbush | Chief Revenue Officer |
| Erick DeVinney | Chief Scientific Officer |
| Ivica Ducic | Chief Medical Officer |
| Jens Schroeder Kemp | Chief Marketing Officer |
Board
| Director | Role |
|---|---|
| Paul G. Thomas | Chairman of the Board |
| Alan M. Levine | Director |
| Amy Wendell | Director |
| John H. Johnson | Director |
| Joseph Tyndall | Director |
| Kathy Weiler | Director |
| Michael Dale | President, Chief Executive Officer and Board Director |
| William Burke | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Axogen (NASDAQ:AXGN) Q3 2026 Earnings Call | Wed, Oct 28, 2026 · 8:00 AM ET | Replay |
| Axogen (NASDAQ:AXGN) Q2 2026 Earnings Call | Wed, Jul 29, 2026 · 8:00 AM ET | Replay |
| Axogen (NASDAQ:AXGN) Q1 2026 Earnings Call | Tue, Apr 28, 2026 · 8:00 AM ET | Replay |
| Axogen (NASDAQ:AXGN) Q4 2025 Earnings Call | Tue, Feb 24, 2026 · 8:00 AM ET | Replay |
| Axogen (NASDAQ:AXGN) Q3 2025 Earnings Call | Wed, Oct 29, 2025 · 8:00 AM ET | Replay |
| Axogen (NASDAQ:AXGN) Q2 2025 Earnings Call | Tue, Aug 05, 2025 · 8:00 AM ET | Replay |
| Axogen (NASDAQ:AXGN) Q1 2025 Earnings Call | Thu, May 08, 2025 · 8:00 AM ET | Replay |
| Axogen (NASDAQ:AXGN) Q4 2024 Earnings Call | Tue, Feb 25, 2025 · 8:00 AM ET | Replay |
| Axogen (NASDAQ:AXGN) Q3 2024 Earnings Call | Thu, Nov 07, 2024 · 8:00 AM ET | Replay |
| Axogen (NASDAQ:AXGN) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 8:00 AM ET | Replay |
All 27 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 28, 2026 · Before open | +31.5% |
| Q2 2026 | Jul 29, 2026 · Before open | +0.5% |
| Q1 2026 | Apr 28, 2026 · Before open | +6.6% |
| Q4 2025 | Mar 3, 2026 | −4.7% |
| Q3 2025 | Oct 29, 2025 · Before open | +23.1% |
| Q2 2025 | Aug 5, 2025 · Before open | +9.3% |
| Q1 2025 | May 8, 2025 · Before open | −23.2% |
| Q4 2024 | Feb 25, 2025 | +8.1% |
| Q3 2024 | Nov 7, 2024 · Before open | −13.4% |
| Q2 2024 | Aug 8, 2024 · Before open | +35.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · Before open | −10.4% |
| Q4 2023 | Mar 5, 2024 · Before open | −15.1% |
| Q3 2023 | Nov 7, 2023 · Before open | +36.9% |
| Q2 2023 | Aug 7, 2023 · After close | −19.4% |
| Q1 2023 | May 9, 2023 · Before open | −3.5% |
| Q4 2022 | Mar 14, 2023 · Before open | +11.9% |
| Q3 2022 | Nov 8, 2022 · Before open | +12.9% |
| Q2 2022 | Aug 3, 2022 · After close | +0.3% |
| Q1 2022 | May 4, 2022 · After close | +18.3% |
| Q4 2021 | Feb 22, 2022 · After close | +9.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (November 2026) | Investor day | 18 slides | Nov 9, 2026 |
| Q3 2026 Earnings Presentation | Earnings | 24 slides | Oct 28, 2026 |
| Q3 2026 Earnings Presentation | Earnings | 26 slides | October 2026 |
| Merger or Acquisition (September 2026) | Merger or acquisition | 15 slides | Sep 10, 2026 |
| Investor Presentation (September 2026) | Investor deck | 16 slides | Sep 10, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 23 slides | Jul 29, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 26 slides | July 2026 |
| Investor Presentation (April 2026) | Investor deck | 26 slides | Apr 28, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 21 slides | Apr 28, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 18 slides | Feb 24, 2026 |
All 36 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (January 2026) | Investor deck | 27 slides | Jan 12, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 18 slides | Oct 29, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 18 slides | Aug 5, 2025 |
| Investor Day (March 2025) | Investor day | 73 slides | Mar 4, 2025 |
| Investor Presentation (February 2025) | Investor deck | 46 slides | Feb 25, 2025 |
| Q3 2024 Earnings Presentation | Earnings | 51 slides | Nov 7, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 52 slides | Aug 8, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 50 slides | May 2, 2024 |
| Investor Presentation (March 2024) | Investor deck | 51 slides | Mar 5, 2024 |
| Investor Presentation (January 2024) | Investor deck | 54 slides | Jan 8, 2024 |
| Investor Presentation (November 2023) | Investor deck | 54 slides | Nov 7, 2023 |
| Investor Presentation (August 2023) | Investor deck | 56 slides | Aug 7, 2023 |
| Investor Presentation (January 2023) | Investor deck | 47 slides | Jan 9, 2023 |
| Q3 2022 Earnings Presentation | Earnings | 45 slides | Nov 8, 2022 |
| Q2 2022 Earnings Presentation | Earnings | 44 slides | Aug 3, 2022 |
| Investor Presentation (May 2022) | Investor deck | 44 slides | May 4, 2022 |
| FY2021 Earnings Presentation | Earnings | 42 slides | Feb 22, 2022 |
| Q3 2021 Earnings Presentation | Earnings | 44 slides | Nov 3, 2021 |
| Q2 2021 Earnings Presentation | Earnings | 44 slides | Aug 4, 2021 |
| Q1 2021 Earnings Presentation | Earnings | 44 slides | May 5, 2021 |
| Q4 2020 Earnings Presentation | Earnings | 41 slides | Feb 22, 2021 |
| Investor Presentation (January 2021) | Investor deck | 38 slides | Jan 11, 2021 |
| Investor Presentation (January 2020) | Investor deck | 39 slides | Jan 13, 2020 |
| Investor Day (November 2017) | Investor day | 22 slides | Nov 21, 2017 |
| Investor Presentation (November 2012) | Investor deck | 27 slides | November 2012 |
| Shareholder Meeting (August 2012) | Shareholder meeting | 22 slides | Aug 30, 2012 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Made bigger: about US$124M · US$31 a share · Wells Fargo Securities +3 Dealers: Wells Fargo Securities (lead), Mizuho (lead), Canaccord Genuity, Raymond James Use of proceeds: Early payoff and termination of its Oberland Capital term loan facility, working capital, capital expenditures and general corporate purposes | Jan 22, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 225.2M | 187.3M | 159.0M | 138.6M | 127.4M | 112.3M | 106.7M | 83.9M | 60.4M | 41.1M |
| Cost of revenue | 57.9M | 45.4M | 37.1M | 29.8M | 22.9M | 21.6M | 17.3M | 12.9M | 9.31M | 6.47M |
| Gross profit | 167.4M | 142.0M | 121.9M | 108.8M | 104.4M | 90.7M | 89.4M | 71.0M | 51.1M | 34.6M |
| Research and development | 32.9M | 27.8M | 27.3M | 25.6M | 24.2M | 17.8M | 17.5M | 11.8M | 6.70M | 4.21M |
| Operating income | -7.85M | -3.29M | -21.5M | -29.7M | -25.4M | -23.2M | -31.4M | -20.5M | -7.95M | -8.13M |
| Depreciation and amortization | 6.66M | 6.47M | 4.22M | 2.83M | 2.74M | 1.53M | 933.0K | 774.0K | 488.0K | 362.0K |
| EBITDA | -1.19M | 3.18M | -17.2M | -26.9M | -22.7M | -21.7M | -30.5M | -19.7M | -7.46M | -7.77M |
| Interest expense | 7.70M | 8.21M | 2.83M | 624.0K | 1.36M | 1.05M | 40.0K | 1.21M | 2.22M | 5.39M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -15.7M | -9.96M | -21.7M | -28.9M | -27.0M | -23.8M | -29.1M | -22.4M | -10.4M | -14.4M |
| Earnings per share, basic | -0.34 | -0.23 | -0.51 | -0.69 | -0.65 | -0.60 | -0.74 | -0.60 | -0.31 | -0.47 |
| Earnings per share, diluted | -0.34 | -0.23 | -0.51 | -0.69 | -0.65 | -0.60 | -0.74 | -0.60 | -0.31 | -0.47 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 35.5M | 27.6M | 31.0M | 15.3M | 32.8M | 48.8M | 35.7M | 24.3M | 36.5M | 30.0M |
| Short-term investments | 5.98M | 5.93M | 0 | 33.5M | 51.3M | 55.2M | 60.8M | 92.3M | ||
| Receivables | 26.2M | 24.1M | 25.1M | 22.2M | 18.2M | 17.6M | 16.9M | 15.3M | 11.1M | 8.05M |
| Inventory | 42.4M | 33.2M | 23.0M | 18.9M | 16.7M | 12.5M | 13.9M | 12.0M | 7.32M | 5.46M |
| Current assets | 120.4M | 99.2M | 88.0M | 98.1M | 127.0M | 145.3M | 135.0M | 151.0M | 55.7M | 44.0M |
| Property, plant and equipment | 62.9M | 38.4M | 14.9M | 8.04M | 2.20M | 1.49M | ||||
| Total assets | 221.7M | 203.7M | 196.8M | 195.4M | 208.0M | 201.4M | 154.6M | 160.2M | 58.9M | 46.4M |
| Accounts payable | 2.89M | 8.01M | 11.8M | 8.96M | 5.92M | 4.60M | 8.26M | 4.52M | 3.24M | 3.61M |
| Current liabilities | 23.6M | 30.6M | 30.4M | 23.8M | 24.3M | 22.8M | 20.9M | 13.0M | 13.7M | 11.1M |
| Long-term debt | 48.4M | 47.5M | 46.6M | 45.7M | 44.8M | 32.0M | 0 | 35.0K | 19.8M | 20.3M |
| Total debt | 48.4M | 47.5M | 46.6M | 45.7M | 44.8M | 32.0M | 0 | 63.0K | 20.5M | 20.3M |
| Total liabilities | 92.8M | 99.8M | 101.2M | 94.4M | 95.5M | 78.2M | 22.5M | 13.2M | 33.7M | 31.4M |
| Shareholders' equity | 128.8M | 103.9M | 95.7M | 101.0M | 112.5M | 123.1M | 132.2M | 147.0M | 25.2M | 14.9M |
| Shares outstanding | 47.2M | 44.1M | 43.1M | 42.4M | 41.7M | 40.6M | 39.6M | 38.9M | 34.4M | 33.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 812.0K | 4.54M | -5.72M | -16.1M | -13.4M | -9.63M | -19.9M | -17.9M | -9.24M | -11.2M |
| Capital spending | -3.75M | -3.10M | -13.9M | -20.1M | -27.8M | -21.9M | -4.66M | -6.28M | -1.10M | -931.0K |
| Free cash flow | -2.93M | 1.43M | -19.6M | -36.1M | -41.2M | -31.5M | -24.5M | -24.1M | -10.3M | -12.2M |
| Cash from investing | -5.32M | -10.3M | 19.3M | -3.20M | -23.6M | -17.0M | 27.3M | -98.2M | -1.29M | -1.16M |
| Cash from financing | 10.5M | 2.29M | 1.95M | 1.79M | 20.5M | 40.5M | 4.03M | 109.8M | 17.0M | 16.5M |
| Change in cash | 5.99M | -3.47M | 15.5M | -17.5M | -16.6M | 13.9M | 11.4M | -6.21M | 6.49M | 4.11M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 9, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Oct 28, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 28, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 1, 2026 | Current report | SEC |
| 424B5 · Prospectus | Sep 10, 2026 | Offer document | SEC |
| 8-K/A · Current report, amended | Sep 10, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 10, 2026 | Material contract | SEC |
| 4 · Change in ownership | Sep 4, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Sep 2, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 10, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 7, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 31, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Jul 29, 2026 | Quarterly report | SEC |
| 8-K · Current report | Jul 29, 2026 | Results | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 8, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 7, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 7, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 7, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | Apr 28, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 28, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 10-K · Annual report | Feb 24, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 24, 2026 | Results | SEC |
| 8-K · Current report | Jan 23, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 23, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jan 21, 2026 | Offer document | SEC |
| S-3ASR · Registration statement | Jan 21, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 11, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 8, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 5, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 3, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 30, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 29, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Oct 29, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 29, 2025 | Results | SEC |
| 4 · Change in ownership | Oct 24, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 3, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 2, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 25, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Aug 5, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 10, 2025 | Other filings | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 22, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | May 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 16, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 2, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 30, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 30, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 7, 2025 | Current report | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 19, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 4, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Mar 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 26, 2025 | Insider trade | SEC |
| 10-K · Annual report | Feb 26, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 3, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jan 21, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 14, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 10, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 8, 2025 | Big-stake notice | SEC |
| 5 · Annual statement of ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 7, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 144 · Notice of proposed sale | Nov 7, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 13, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Sep 10, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Sep 6, 2024 | Current report | SEC |
| 144 · Notice of proposed sale | Sep 5, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 4, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 21, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 12, 2024 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 9, 2024 | Offer document | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 9, 2024 | Insider trade | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Axogen, Inc.’s releases · as of Oct 26, 2026
- Common shares
- 59,730,715
- Fully diluted
- 59,730,715
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 59,730,715 | Oct 26, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 26, 2026 | 59,730,715 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| John H. Johnson Other companies: Xeris Biopharma Holdings, Inc. (Independent, Non-executive Board Member · Since at least Oct 5, 2021); Verastem, Inc. (Director · Since at least Apr 23, 2020); Applied Therapeutics Inc (Executive Chairman, Director · Dec 19, 2024 – Dec 19, 2024 · Past); Melinta Therapeutics Inc (Chief Executive Officer, Director · Jun 12, 2018 – Jun 27, 2019 · Past); AVEO Pharmaceuticals Inc (Director · Feb 1, 2018 – Feb 1, 2018 · Past); Strongbridge Biopharma plc (Chief Executive Officer, Director · Jan 1, 2018 – Oct 5, 2021 · Past); Cempra Inc (Director · Jan 3, 2017 – Jan 3, 2017 · Past); Ocugen, Inc. (Director · Dec 16, 2016 – Jun 15, 2018 · Past); Portola Pharmaceuticals Inc (Director · Jun 17, 2016 – Jul 2, 2020 · Past); Sucampo Pharmaceuticals Inc (Director · Jun 2, 2016 – Feb 13, 2018 · Past) | Director · Since at least Jul 19, 2021 |
| Paul G. Thomas Other companies: TELA Bio, Inc. (Director · Since at least Apr 30, 2026); Surgalign Holdings Inc (Director · Mar 8, 2019 – Aug 15, 2022 · Past); RTI Surgical Holdings Inc (Director · May 26, 2016 – Mar 8, 2019 · Past); Roka Bioscience Inc (President and CEO, Director · Jul 16, 2014 – Nov 10, 2016 · Past); Aegerion Pharmaceuticals Inc (Director · Aug 1, 2011 – Nov 29, 2016 · Past); ABIOMED Inc (Director · May 26, 2011 – Dec 22, 2022 · Past); Kinetic Concepts Inc (President, LifeCell Corp. · May 20, 2008 – Aug 25, 2008 · Past); Orthovita Inc (Director · Jul 27, 2007 – Jun 24, 2011 · Past); Avanir Pharmaceuticals Inc (Director · Feb 13, 2006 – Mar 1, 2007 · Past); Lifecell Corp (Chairman, President and CEO, Director · Jan 3, 2006 – May 19, 2008 · Past) | Chairman of the Board · Since at least Sep 30, 2020 |
| Quentin Blackford Other companies: Align Technology, Inc. (Director · Since at least Aug 27, 2026); iRhythm Holdings, Inc. (President, Chief Executive Officer and Director · Since at least Oct 4, 2021); Alphatec Holdings, Inc. (Director · Since at least Oct 2, 2017); Paragon 28 Inc (Director · Aug 1, 2022 – Apr 21, 2025 · Past); DexCom, Inc. (Chief Operating Officer · Sep 7, 2017 – Sep 8, 2021 · Past); NuVasive Inc (CFO · Jul 1, 2016 – Feb 8, 2017 · Past) | Director · Apr 26, 2019 – Mar 30, 2022 · Past |
| Guido J. Neels Other companies: TELA Bio, Inc. (Director · Since at least Apr 30, 2026); Elutia, Inc. (Director · Since at least Oct 9, 2025); Bioventus Inc. (Director · Since at least Feb 11, 2021); Entellus Medical Inc (Director · Jun 14, 2016 – Feb 28, 2018 · Past); Endologix Inc (Director · Nov 3, 2015 – Apr 3, 2019 · Past) | Director · Since at least Aug 26, 2015 |
| Lisa N Colleran Other companies: TELA Bio, Inc. (Director · Since at least Apr 20, 2020); Establishment Labs Holdings Inc. (Director · Jul 18, 2018 – Jun 17, 2022 · Past); Rockwell Medical, Inc. (Director · Mar 7, 2018 – Jun 6, 2019 · Past); Kinetic Concepts Inc (Global President, LifeCell · Aug 27, 2008 – Nov 4, 2011 · Past); Lifecell Corp (SVP Commercial Operations · Jan 3, 2006 – May 19, 2008 · Past) | Director · Jul 9, 2018 – Jul 9, 2018 · Past |
| Amy Wendell Other companies: Hologic Inc (Director · Since at least Feb 26, 2026); Baxter International Inc. (Director · Since at least May 6, 2025); Solventum Corporation (Director · Since at least Apr 30, 2025) | Director · Since at least Jun 9, 2025 |
| Karen Zaderej Other companies: EyePoint, Inc. (Board Member · Since at least Jul 11, 2022); Viveve Medical, Inc. (Director · Apr 1, 2019 – Nov 26, 2019 · Past) | CEO, Director · May 29, 2019 – Mar 16, 2024 · Past |
| Robert James Rudelius Other companies: PetVivo Holdings Inc (Director · Since at least Jan 3, 2018); ProUroCare Medical Inc. (Director · Feb 28, 2008 – Sep 10, 2013 · Past) | Director · Sep 22, 2010 – Sep 30, 2020 · Past |
| Kathy Johnson Weiler Other companies: American Well Corporation (Chief Comm. & Growth Officer · Jun 1, 2023 – Dec 2, 2024 · Past) | Director · Since at least Dec 20, 2023 |
| Kathy Weiler Other companies: Solventum Corporation (Chief Transformation and Enterprise Services Officer · Since at least Nov 4, 2026) | Director · Since at least Aug 11, 2026 |
All 35 people
| Person | Seat |
|---|---|
| Michael Dale Other companies: CVRx, Inc. (Chief Executive Officer and President · Since at least Apr 20, 2026) | President, Chief Executive Officer and Board Director · Since at least Oct 28, 2026 |
| William Burke Other companies: Miromatrix Medical Inc (Director · Dec 12, 2023 – Dec 12, 2023 · Past) | Director · Since at least Jun 6, 2024 |
| Alan M. Levine | Director · Since at least Apr 26, 2019 |
| Al Jacks | Vice President of Quality · Nov 4, 2026 – Nov 4, 2026 · Past |
| Amalia De Luca | Vice President of Planning and Business Development · Nov 4, 2026 – Nov 4, 2026 · Past |
| Angelo Scopelianos | Chief R&D Officer · Sep 4, 2018 – Mar 16, 2024 · Past |
| Bradley Ottinger | General Counsel and CCO · Jun 1, 2020 – Mar 16, 2023 · Past |
| Daniel C Sigg | Director · Nov 21, 2006 – Sep 26, 2008 · Past |
| David K Hansen | VP Finance & Treasurer · Dec 28, 2015 – Aug 21, 2019 · Past |
| Doris Quackenbush | Chief Revenue Officer · Since at least May 1, 2026 |
| Erick DeVinney | Chief Scientific Officer · Since at least Dec 18, 2017 |
| Ivica Ducic | Chief Medical Officer · Since at least Nov 4, 2026 |
| Jamie Mark Grooms | Director · Sep 30, 2011 – Aug 14, 2019 · Past |
| Jens Schroeder Kemp | Chief Marketing Officer · Since at least Jan 1, 2024 |
| Jesse Bishop | Vice President of Regulatory · Nov 4, 2026 – Nov 4, 2026 · Past |
| John P Engels | VP · Sep 30, 2011 – Jun 8, 2017 · Past |
| Joseph Tyndall | Director · Since at least Jun 6, 2024 |
| Kevin Christopher Worms-Lynch | Director · Sep 22, 2010 – Nov 1, 2010 · Past |
| Lindsey Hartley | Chief Financial Officer · Since at least May 12, 2025 |
| Marc Began | EVP & General Counsel · Since at least Dec 4, 2025 |
| Mark Louis Friedman | VP Regulatory Affairs & Policy · Sep 30, 2011 – Mar 16, 2022 · Past |
| Paris Dally | Vice President, Operations · Nov 4, 2026 – Nov 4, 2026 · Past |
| Rick Ditto | VP, Global Health Economics, Reimbursement & Policy · Nov 4, 2026 – Nov 4, 2026 · Past |
| Stacy Arnold | Vice President of Product Development and Research · Nov 4, 2026 – Nov 4, 2026 · Past |
| Todd Goede | Vice President and General Manager, NerveTape® Operations · Nov 4, 2026 – Nov 4, 2026 · Past |
Log in to ask 6ix AI your own questions about Axogen, Inc.